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Immune checkpoint inhibitors targeting programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 have
improved survival in patients with metastatic melanoma, especially in combination (i.e., ipilimumab-nivolumab). Postmarketing
surveillance has identified rare but at times life-threatening adverse effects associated with these agents in combination and as
monotherapy, which include myocarditis, myositis, myasthenia gravis (MG), and hepatotoxicity. Further evaluation of immune
checkpoint therapy-induced MG identified the rapid clinical progression, prolonged treatment/supportive therapy course, and
higher frequency of myasthenic crisis in these patients versus those with idiopathic MG. More rapid incorporation of aggressive
treatment options (i.e., intravenous immunoglobulin, plasmapheresis) may be necessary in these cases. Anti-striational antibodies
are often detected in individuals with myasthenia gravis and concurrent myositis and myocarditis. A high-index of suspicion is
necessary to assist with rapid treatment initiation as these patients can rapidly deteriorate into respiratory compromise. A case
of a 78-year-old woman with metastatic melanoma status after combination therapy with ipilimumab-nivolumab that developed
transaminitis, myositis, myocarditis, andmyasthenia gravis (with positive anti-striational antibodies) five days after the first cycle, is
presented. Despite high dose intravenous methylprednisolone and intravenous immunoglobulin treatment, she ultimately entered
hospice care eight days after hospital admission, 36 days after her first cycle.
1. Introduction
Immune checkpoint inhibitors (ICIs) are a class of medica-
tions that include programmed cell death protein 1 (PD-1)
inhibitors (nivolumab) and cytotoxic T-lymphocyte associ-
ated protein 4 (CTLA-4) inhibitors (ipilimumab) that disin-
hibit the immune system and antitumor immune response
by blocking immune checkpoint cytokines [1]. The immune
checkpoint molecules PD-1 and CTLA-4 have been found to
be expressed on human cancers and serve to decrease T-cell
activation and induce anergy [1]. The ICIs stimulate a robust
immune response leading to a potent antineoplastic effect
and several immune-related adverse effects (irAEs) including
myositis, myocarditis, myasthenia gravis (MG), hepatotoxic-
ity, hypothyroidism, and Miller-Fisher syndrome [1–3].
Myocarditis induced by ICIs, often occurring after the
first or second cycle of therapy, has been reported in 1% of
patients, with death occurring in half of the cases [4–6]. It
cooccurs with myositis and MG in 25% and 11% of patients,
respectively [4–6]. ICI-induced myocarditis and myositis
can also be associated with concomitant MG, but overall
neurologic irAEs occur in less than 1% of patients treated
with ICIs [5, 7]. Here we report a rare case of nivolumab-
ipilimumab induced MG (anti-striational antibody positive)
with associated myositis, myocarditis, and transaminitis in a
patient with metastatic melanoma.
2. Case Presentation
A 78-year-old woman with a past medical history signifi-
cant for hypertension, intermittent asthma, prior pulmonary
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Table 1: Treatment during hospital stay by day.
Treatment 1 (Admission) 2 3 4 5 6 7 8
Methylprednisolone IV 75 mg 125 mg 125 mg 1000 mg 1000 mg 1000 mg 150 mg 75 mg
IVIG 2 mg/kg 2 mg/kg
Plasmapheresis 1st cycle
embolism, depression, and melanoma status after wide local
excision four decades ago, was diagnosed with metastatic
melanoma. Whole body positron emission tomography
(PET) identified multiple metastatic lesions dispersed within
the chest wall, lungs, lymph nodes, and axial skeleton. Com-
bination immunotherapy with ipilimumab and nivolumab
for four cycles, followed by nivolumab maintenance, was
initiated.
Five days following the first cycle of combination
immunotherapy, the patient developed diplopia and proxi-
mal muscle weakness/myalgias. Magnetic resonance imaging
(MRI) was negative for metastatic disease within the brain or
extraocular muscles. Given that her only other medications
included amlodipine and escitalopram, it was hypothesized
that these symptoms were adverse reactions to combination
immunotherapy. Ipilimumab-nivolumab therapy was held
and she received methylprednisolone intravenously (IV) in
the clinic at a dose of 1 mg/kg body weight (75 mg).
Assessment in the hospital demonstrated abducens nerve,
upward and downward gaze palsies, along with unsteady gait,
and a diffuse rash. Patient had weakness and myalgias of
proximal muscles bilaterally, greater in the lower extremities,
and decreased vibratory sensation in the distal extremities.
Vitamin B12 level was within normal limits and rapid plasma
reagin (RPR)was nonreactive.Dosage ofmethylprednisolone
was increased to 125 mg IV daily (1.5 mg/kg) due to severe
clinical presentation. Routine dosing for acute myositis is
methylprednisolone IV at 0.5-1.5 mg/kg; pulse therapy of
1000mg IVdaily for 3 to 5 days in cases of severemyositis/lack
of response or intravenous immunoglobulin (IVIG) can be
initiated at 2 g/kg [8].
Labs demonstrated an elevated creatine phosphokinase
(CPK) of 9198 IU/L, along with a transaminitis with an
aspartate aminotransferase (AST) of 683 IU/L and an alanine
aminotransferase (ALT) of 315 IU/L. C-reactive protein was
elevated at 39.5 mg/L. Erythrocyte sedimentation rate and
thyroid stimulating hormone (TSH) were within normal
limits, and hepatitis panel was negative. Myositis panel was
negative for myositis-related antibodies, including Jo-1, PL-7,
PL-12, EJ, OJ, SRP,Mi-2 alpha,Mi-2 beta,MDA-5, TIF-1y, and
NXP-2. Due to concern for immunotherapy-relatedmyositis,
methylprednisolone therapy was continued at a dose of
125 mg IV daily. Lower extremity MRI identified moderate
edema of the subcutaneous tissue, superficial fascia, and
muscles consistent with myositis. The patient’s troponin-I
level was 8.57 ng/mL. Transthoracic echocardiogram (TTE)
was within normal limits, consistent with immunotherapy-
related myocarditis.
The patient had persistent proximal muscle weakness
and worsening gaze palsies that were minimally responsive
to steroid therapy. The dose of methylprednisolone was
increased from 125 mg IV to pulse steroid dosing of 1000
mg IV daily, for a total of three days. The patient developed
new bulbar symptoms including dysphagia, voice hoarseness,
and ultimate respiratory distress, and inability to manage
secretions. Due to bulbar symptoms refractory to high dose
steroid therapy, IVIG was started at a dose of 2 g/kg IV daily
for two days. A summary of the patient’s treatment during her
hospital stay can be seen in Table 1.
Muscle weakness mildly improved with IVIG and IV
steroid therapy, but bulbar symptoms progressively wors-
ened. IVIG therapy for severe myositis is generally loaded at
2 g/kg IV for one to two doses and then repeated every four to
eight weeks. Given that the patient had already received two
loading doses of IVIGwith worsening clinical status, plasma-
pheresis was initiated. Anti-GQ1B was tested to evaluate for
Miller-Fisher syndrome and was negative. Patient developed
bilateral ptosis and increased respiratory effort, necessitating
transfer to the intensive care unit (ICU). Anti-striational
antibodies were found to be positive, with an elevated titer
of 1:80, supporting a diagnosis of ICI-induced MG.
The patient’s clinical condition continued to deteriorate,
with progressively worsening dysphagia, increased respira-
tory effort, decreased ability tomanage respiratory secretions,
complete gaze palsy, severe ptosis, and continued proximal
muscle weakness. CPK, AST, ALT, and troponins were down-
trending despite worsening symptoms (Table 2). Due to
increased work of breathing, there was concern that the
patient would soon require intubation.The patient expressed
desire to cease aggressive therapy at that time and was
evaluated by the palliative care team. She was deemed to
have full decision making capacity and a prognosis of days
to weeks. She elected to enter hospice care, and given her
increased respiratory effort and inability to manage respira-
tory secretions, she was discharged to inpatient hospice care.
3. Discussion
ICI therapy has been efficacious in the treatment of many
cancers including metastatic melanoma. Despite this success,
ICI therapy is associated with multiple irAEs, some of
which are rare but life-threatening including myocarditis,
myositis, MG, and transaminitis as highlighted in this case
[4]. MG occurs in 0.12% of patients treated with nivolumab
monotherapy, but seldomwith ipilimumabmonotherapy [3].
In comparison to idiopathic MG, patients with nivolumab-
inducedMG (nivoMG) tend to have higher serumCPK levels
and incidence of myocarditis, myositis, and MG [3]. Patients
with nivoMG necessitated more aggressive therapy includ-
ing IVIG and respiratory support, with a mean duration
of 54 days [3]. In this case, methylprednisolone, IVIG,
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Table 2: Selecting laboratory values during hospital stay by day.
1 (Admission) 2 3 4 5 6 7 8
AST 735 613 624 452 332 192 139 60
ALT 373 325 428 388 390 344 271 112
CK 9958 6995 5032 2858 1883 988 556 228
TSH 0.65
CRP 39.5
Troponin I 8.57 󳨀→ 7.56 4.86 4.28 2.80 1.82
BNP 133
ESR 9
and plasmapheresis were ineffective in managing bulbar
symptoms, consistent with documented cases of ICI-induced
MG. Accordingly, earlier initiation of advanced treatment
measures should be consideredwhen suspecting ICI-induced
MG.
Various etiologies could contribute to diplopia and prox-
imal muscle weakness/myalgias. Therefore, a thorough clini-
cal history and laboratory evaluation are required to delineate
the etiology. A myositis panel could identify antibodies asso-
ciated with polymyositis, dermatomyositis, and malignancy-
associatedmyositis. An anti-GQ1B can be attained to evaluate
for Miller-Fisher syndrome [2]. Anti-acetylcholine receptor
antibodies can be identified in both ICI-induced and idio-
pathic MG [3]. In idiopathic MG, anti-striational antibodies
are associated with myositis and/or myocarditis, suggesting
that a similar pathogenic process may occur in irAEs [9].
More severe outcomes, including fatality, were seen in ICI-
induced MG with anti-striational antibodies in comparison
to seronegative cases [10].
This case demonstrates the importance of early screening
for and management of irAEs associated with ipilimumab-
nivolumab therapy as patients can develop rapidly progres-
sive MG with subsequent myasthenic crisis. Additionally,
clinicians should be aware of the more aggressive treatment
and prolonged supportive care often required by patients
with ICI-induced MG, especially those with positive anti-
striational antibodies, and transition to IVIG/plasmapheresis
earlier in the treatment plan. This case further highlights
the possible role of anti-striational antibody detection in
prognosticating patients with ICI-induced MG.
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